PT Diastika Biotekindo TbkISX:CHEK 2 EBITDA Margin % is 0.00% as of . 20. GuruFocus rates ISX:CHEK with a GF Score™ of 2/100. The stock has 1 warning sign investors should review. Among 815 Medical Devices & Instruments companies, PT Diastika Biotekindo Tbk ranks worse than 122699.26% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
PT Diastika Biotekindo Tbk EBITDA Margin % Related Terms
PT Diastika Biotekindo Tbk EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Diastika Biotekindo Tbk EBITDA Margin % Chart
PT Diastika Biotekindo Tbk Annual Data
Trend
EBITDA Margin %
PT Diastika Biotekindo Tbk Semi-Annual Data
EBITDA Margin %
ISX:CHEK vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, PT Diastika Biotekindo Tbk's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Diastika Biotekindo Tbk EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PT Diastika Biotekindo Tbk's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where PT Diastika Biotekindo Tbk's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Diastika Biotekindo Tbk (ISX:CHEK) has a EBITDA Margin % of 0.00% as of . 20. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PT Diastika Biotekindo Tbk and its competitors. According to the industry distribution chart, PT Diastika Biotekindo Tbk ranks #999999 out of 815 companies in the Medical Devices & Instruments industry.
Is PT Diastika Biotekindo Tbk's EBITDA Margin % too high?
PT Diastika Biotekindo Tbk's current EBITDA Margin % is 0.00%. Based on the distribution chart, PT Diastika Biotekindo Tbk ranks #999999 out of 815 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, PT Diastika Biotekindo Tbk has a GF Score™ of 2/100, reflecting its overall financial health beyond just this single metric.
How does PT Diastika Biotekindo Tbk's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, PT Diastika Biotekindo Tbk ranks #999999 out of 815 companies for EBITDA Margin %. This places PT Diastika Biotekindo Tbk in the lower half of its industry. The industry median EBITDA Margin % is 7.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.47, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PT Diastika Biotekindo Tbk and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Diastika Biotekindo Tbk's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Diastika Biotekindo Tbk stock overvalued right now?
PT Diastika Biotekindo Tbk (ISX:CHEK) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. PT Diastika Biotekindo Tbk's overall GF Score™ is 2/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For PT Diastika Biotekindo Tbk (ISX:CHEK), the current EBITDA Margin % is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AddressJalan Rawagelam V, Kawasan Industri Pulogadung, Block L, No. Kav 11-13, Gedung Etana Lantai 3, Desa/Kelurahan Jatinegara, Kec. Cakung, Kota Adm. Jakarta Timur, Jakarta, IDN, 13930
PT Diastika Biotekindo Tbk is engaged in providing medical and laboratory equipment solutions in Indonesia. It is engaged in the wholesale trading of laboratory equipment, pharmaceutical products, and medical devices for human use. The company is also involved in wholesale trading of radioactive substances and ionizing radiation generators, and undertakes activities related to the testing and/or calibration of medical devices, as well as the inspection of healthcare facilities and infrastructure. Its product offerings mainly include devices like hematology analyzer, pipette, hemoglobin testing system, etc. The company's operating segments are: Diagnostics Group, which generates the maximum revenue, and Life Sciences Group. Geographically, all of its revenue is derived from Indonesia.
2GF Score
Get the complete analysis for ISX:CHEK
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:CHEK has been successfully added to your 